U.S. Markets open in 8 hrs 51 mins

GW Pharmaceuticals plc (GWPH)

NASDAQ Global Market - NASDAQ Global Market Delayed Price. Currency in USD
Add to watchlist
99.62+0.87 (+0.88%)
At close: 4:00PM EDT
People also watch
INSYCARATRTCCANNTWMJF
Full screen
Previous Close98.75
Open98.45
Bid0.00 x 0
Ask0.00 x 0
Day's Range98.45 - 100.63
52 Week Range79.62 - 137.88
Volume224,481
Avg. Volume298,090
Market Cap2.52B
Beta2.32
PE Ratio (TTM)-23.48
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • A Record Number of Americans Have Tried Marijuana, New Survey Shows
    Motley Fool3 days ago

    A Record Number of Americans Have Tried Marijuana, New Survey Shows

    Approximately 112 million adults have tried cannabis at least once.

  • GW Pharmaceuticals PLC- ADR (GWPH) Stock Is High-Risk, High Reward
    InvestorPlace4 days ago

    GW Pharmaceuticals PLC- ADR (GWPH) Stock Is High-Risk, High Reward

    Marijuana has been making headlines for some time now as more and more states vote to legalize it. Considering the way the cannabinoids work, it makes sense that the main application for medical marijuana would be for neurological disorders — something GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) was quick to latch on to. GWPH’s main focus is pediatric epilepsy (although it does hope to use its proprietary cannabinoid product platform for a broad range of diseases down the road), a neurological disorder marked by recurrent seizures.

  • Benzinga5 days ago

    What's The Difference Between Zynerba and GW Pharma's Epilepsy Drugs?

    The month of August has been hard one for cannabis drug stocks. After Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) reported a pair of disappointing trial results in its Phase 2 STAR 1 and STOP trials, respectively, ...